Last Updated: May 26, 2026

Claims for Patent: 10,086,047

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,086,047

Title:	Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Abstract:	The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
Inventor(s):	Per Sauerberg, Simon Bjerregaard, Flemming S. Nielsen
Assignee:	Novo Nordisk AS
Application Number:	US15/019,412
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,086,047
Patent Claims:	1. A solid pharmaceutical composition for oral administration comprising: 0.5 to 2.5 μmol N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib 8,Arg34]GLP-1(7-37) and 0.8-1.3 mmol of a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, wherein the solid pharmaceutical composition has surface eroding or co-release properties, and a disintegration time of 7-15 minutes. 2. The composition according to claim 1, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is selected from the group consisting of the sodium salt, potassium salt and calcium salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. 3. The composition according to claim 2, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC). 4. The composition according to claim 3, wherein said composition is in the form of a tablet. 5. The composition according to claim 4, wherein said tablet has a weight between 300-500 mg. 6. The composition according to claim 2, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is selected from the group consisting of the potassium salt and calcium salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. 7. The composition according to claim 2, wherein said composition is in the form of a tablet. 8. The composition according to claim 7, wherein said tablet has a weight between 300-500 mg. 9. The composition according to claim 6, wherein said composition is in the form of a tablet. 10. The composition according to claim 9, wherein said tablet has a weight between 300-500 mg.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.